News NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
News Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer.
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
News First MHRA/NICE aligned guidance due in June The aligned regulatory pathway for UK drugs regulator MHRA and reimbursement authority NICE gets underway on 1st April.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
